

IMPACT OF PHARMACEUTICAL INTERVIEW IN PATIENT ACCEPTANCE OF INSULIN GLARGINE'S BIOSIMILAR 100UI/ML



M. Malassigné¹, M. Megne-Wabo¹, V. Rigalleau², K. Mohammedi², F. Xuereb^{1,3}, D. Breilh^{1,3}.
 1. Bordeaux University Hospital, Pharmacy Department, Bordeaux, France.
 2. Bordeaux University Hospital, Diabetology Department, Bordeaux, France.
 3. University Of Bordeaux, Inserm 1034 - Pharmacokinetics And Pharmacodynamics PK/PD, Bordeaux, France.



BACKGROUND

- Insulin glargine's biosimilar (IB) → far less costly for the health care system
- Prescription of biosimilar → not yet predominant
- Patient → must give his **consent** to be prescribed a biosimilar

OBJECTIVES

Our study is aimed to **assess the knowledge of diabetics patients about their insulin glargine therapy and biosimilars**, and then to assess the **impact of a pharmaceutical interview** in IB patient acceptance.

MATERIAL AND METHODS

QUESTIONNAIRE PATIENT BIOSIMILAIRE

Name: _____ Date: _____

	YES	NO
1 Do you know what a biologic meds is?		
2 Do you know what a biosimilar is?		
3 If yes, give a definition		
4 If yes, how did you get the information? Média : _____ Relatives : _____ filed : _____ Adresse : _____		
5 Do you know the biosimilar of you insulin?		
6 Do you want to have information about biosimilar?		
7 Explications given		
8 Other questions of patient :		
9 If your doctor would purpose to switch to a biosimilar, would you agree?		
10 What are the reasons ?		

Realized by: _____

PHARMACEUTICAL INTERVIEW




Realization of a **prospective study** in our diabetology department, inclusion of all hospitalized patients with insulin glargine.

Figure 1 : Questionnaire for patients

RESULTS

Characteristics	Study Cohort(n=54)
Patients	
Age, years, mean (S.D.)	51 (19.51)
Sex Ratio	0,64
Disease characteristics	
Type 1 Diabetes	26 (48%)
Type 2 Diabetes	22 (41%)
Other diabetes	6 (11%)
Insulinothérapie characteristics	
Start insulinothérapie, years, mean (S.D.)	2006 (12.33)
Biosimilars	9 (18%)
Reason of hospitalization	
Diabete desequilibrate	41 (76%)
Diabete discover	5 (9%)
Other	8 (15%)

PATIENTS



SWITCH TO BIOSIMILAR → QUOTES FROM PATIENTS

YES : WHY ?

- ✓ « Yes, because it seems to be equivalent »
- ✓ « If my doctor prescribe it, i trust him »
- ✓ « Yes, because it's a progress and it is good for the research »



NO : WHY ?

- ✗ « No, because i'm scared of side effects »
- ✗ « No, i'm scared that it wouldn't be as efficient »

CONCLUSION

The **development of pharmaceutical interviews is a key point** to improve the acceptance of biosimilar considering the lack of knowledge of patients about their treatments.

